A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes.

Trial Profile

A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Insulin degludec/insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 28 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Dec 2009 Planned end date changed from 1 Feb 2010 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 15 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top